-+ 0.00%
-+ 0.00%
-+ 0.00%

United Therapeutics Announces First Clinical Xenotransplant In Its EXTEND Study Of UThymoKidney In Patients With ESRD

Benzinga·11/20/2026 12:04:03

The EXTEND study is the first clinical trial to evaluate xenotransplantation of a porcine thymokidney in a patient with end-stage renal disease (ESRD)

EXTEND is the second clinical trial in United Therapeutics’ xeno-organ manufacturing program

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced thefirst clinical xenotransplant in its EXTEND study of the UThymoKidney™ in patients with ESRD. The transplant operation was performed at NYU Langone Health.

The ongoing EXTEND study will evaluate the safety and efficacy of the UThymoKidney in ESRD patients who are not eligible for conventional allogeneic kidney transplantation or who are on an Organ Procurement and Transplantation Network (OPTN) kidney transplant waitlist, but are more likely to die or go untransplanted within five years than receive a kidney transplant.

United Therapeutics’ investigational UThymoKidney is a xenokidney that contains porcine thymic tissue and is derived from a pig with a single gene edit. The pig’s thymus tissue is intended to condition the recipient’s immune system to recognize the UThymoKidney as "self" and reduce the likelihood of organ rejection. The single gene responsible for the synthesis of alpha-gal, a sugar on the surface of cells that can cause immediate rejection of a porcine organ when transplanted into the human body, has been inactivated in the pig’s genome.